Literature DB >> 9242569

Hepatitis C and G virus infection and liver dysfunction after allogeneic bone marrow transplantation: results from a prospective study.

E Rodriguez-Iñigo1, J F Tomás, V Gómez-García de Soria, J Bartolomé, I Pinilla, M J Amaro, V Carreño, J M Fernández-Rañada.   

Abstract

Acute and chronic liver dysfunction is common after allogeneic bone marrow transplantation (BMT). Although toxicity, graft versus-host disease (GVHD), and viral infections are the major causes, etiologic diagnosis is difficult and often remains unknown. We conducted a prospective study to establish the role of the infection with both the hepatitis C virus (HCV) and the recently discovered hepatitis G virus (HGV) in liver dysfunction after BMT. From January 1994 to December 1995, 59 patients who had undergone an allogeneic BMT at our institution were enrolled in the study. HGV-RNA was identified in serum by nested polymerase chain reaction (PCR), and HCV was studied by the presence of second generation enzyme-linked immunosorbent assay (ELISA)-antibodies and HCV-RNA by nested PCR. HGV-RNA was detected in 25 patients (42%) (before BMT in 18 and after BMT in 7). HCV-RNA was present in 12 patients (20%) (before BMT in 11 and after BMT in one). The presence of HCV-RNA and HGV-RNA was clearly associated with a previous history of blood transfusions. No significant association was found between viral infection and acute liver toxicity. Some degree of liver dysfunction was present 6 months after BMT in 25 of 40 evaluable patients (62%). Long-term liver dysfunction was more common among patients infected with HCV alone (3 of 4) or with both HCV and HGV (3 of 3) than in those infected with either HGV alone (eight of 13) or with no virus infection (10 of 20). We found a high prevalence of HGV infection in our BMT population. However, no role for HGV in liver disease could be established in this study, and the relationship between HGV infection and liver dysfunction requires further clarification.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9242569

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  A prospective study on HGV infection after transfusion in pediatric hematological children.

Authors:  L Zhang; G Pen; Q Hu
Journal:  J Tongji Med Univ       Date:  1998

2.  Retrospective study on the impact of hepatitis B and hepatitis C virus infection on hematopoietic stem cell transplantation in Japan.

Authors:  Motohiro Hamaguchi; Hironori Yamada; Hisashi Gondo; Yoshinobu Takemoto; Yasuo Morishima; Yoshihisa Kodera
Journal:  Int J Hematol       Date:  2002-04       Impact factor: 2.490

3.  Hepatic late adverse effects after antineoplastic treatment for childhood cancer.

Authors:  Renée L Mulder; Dorine Bresters; Malon Van den Hof; Bart Gp Koot; Sharon M Castellino; Yoon Kong K Loke; Piet N Post; Aleida Postma; László P Szőnyi; Gill A Levitt; Edit Bardi; Roderick Skinner; Elvira C van Dalen
Journal:  Cochrane Database Syst Rev       Date:  2019-04-15

4.  No increased mortality from donor or recipient hepatitis B- and/or hepatitis C-positive serostatus after related-donor allogeneic hematopoietic cell transplantation.

Authors:  M Tomblyn; M Chen; M Kukreja; M D Aljurf; F Al Mohareb; B J Bolwell; J-Y Cahn; M H Carabasi; R P Gale; R E Gress; V Gupta; G A Hale; P Ljungman; R T Maziarz; J Storek; J R Wingard; J-A H Young; M M Horowitz; K K Ballen
Journal:  Transpl Infect Dis       Date:  2012-05-01       Impact factor: 2.228

5.  Target Enrichment Metagenomics Reveals Human Pegivirus-1 in Pediatric Hematopoietic Stem Cell Transplantation Recipients.

Authors:  Natali Ludowyke; Worakorn Phumiphanjarphak; Nopporn Apiwattanakul; Suwimon Manopwisedjaroen; Samart Pakakasama; Insee Sensorn; Ekawat Pasomsub; Wasun Chantratita; Suradej Hongeng; Pakorn Aiewsakun; Arunee Thitithanyanont
Journal:  Viruses       Date:  2022-04-12       Impact factor: 5.818

6.  Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies.

Authors:  Carlos A Ramos; Rima M Saliba; Leandro de Pádua; Ola Khorshid; Elizabeth J Shpall; Sergio Giralt; Poliana A Patah; Chitra M Hosing; Uday R Popat; Gabriela Rondon; Issa F Khouri; Yago L Nieto; Richard E Champlin; Marcos de Lima
Journal:  Haematologica       Date:  2009-01-14       Impact factor: 9.941

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.